期刊
NANOMEDICINE
卷 7, 期 4, 页码 553-564出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.11.145
关键词
cryopreservation; fertility; nanoliter droplet vitrification; oocyte
资金
- NIH [UL1DE019581, RL1DE019021, R21HL095960, R21EB007707, R01AI081534, R21AI087107]
- W.H. Coulter Foundation
- Center for Integration of Medicine and Innovative Technology (CIMIT) under the US Army
- NIH from the Eunice Kennedy Shriver National Institute of Child Health & Human Development [K12HD001255]
- Presidential New Investigator Award
- Klarman Family Foundation
Aim: Oocyte cryopreservation remains largely experimental, with live birth rates of only 2-4% per thawed oocyte. In this study, we present a nanoliter droplet technology for oocyte vitrification. Materials & methods: An ejector-based droplet vitrification system was designed to continuously cryopreserve oocytes in nanoliter droplets. Oocyte survival rates, morphologies and parthenogenetic development after each vitrification step were assessed in comparison with fresh oocytes. Results: Oocytes were retrieved after cryoprotectant agent loading/unloading, and nanoliter droplet encapsulation showed comparable survival rates to fresh oocytes after 24 h in culture. Also, oocytes recovered after vitrification/thawing showed similar morphologies to those of fresh oocytes. Additionally, the rate of oocyte parthenogenetic activation after nanoliter droplet encapsulation was comparable with that observed for fresh oocytes. This nanoliter droplet technology enables the vitrification of oocytes at higher cooling and warming rates using lower cryoprotectant agent levels (i.e., 1.4 M ethylene glycol, 1.1 M dimethyl sulfoxide and 1 M sucrose), thus making it a potential technology to improve oocyte cryopreservation outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据